Armed with $16M, Cue Biopharma Aims for Selective Immunotherapy – Xconomy
Xconomy |
Armed with $16M, Cue Biopharma Aims for Selective Immunotherapy
Xconomy Cue is now unveiling its immunotherapy approach, along with $16.4 million in new capital, led by MDB Capital Group. The investment follows $10 million in seed funding the company raised after it was founded in 2015. The technology underlying Cue's … Cue Biopharma Debuts With $26 Million in Invested Capital to Develop Next-Generation Biologics to Selectively … |
